SEC Form 4 · accession 0001237566-26-000003
Adaptive Biotechnologies Corp · ADPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter M Neupert
Director
Period of report
Aug 17, 2026
Accepted (ET)
Aug 19, 2026 · 8:07 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001478320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 17, 2026 | M | 15,000 | $6.32 | A | 255,315 | D | |
| Common StockF1 | Aug 17, 2026 | S | 15,000 | $25.23 | D | 240,315 | D | |
| Common StockF2 | Aug 17, 2026 | S | 40,000 | $25.10 | D | 200,315 | D | |
| Common StockF3 | Aug 17, 2026 | S | 69,690 | $25.16 | D | 130,625 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $6.32 | Aug 17, 2026 | M | 15,000 | D | Oct 18, 2026 | — | Common Stock | 15,000 | 0 | D |
Explanation of responses
- F1The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.21 to $25.27, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.06 to $25.17, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.14 to $25.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4The option was fully vested and exercisable and would have expired on October 18, 2026.